Nevro (NYSE:NVRO) announced today that it priced concurrent underwritten public offerings of more than 1.6 million common stock shares, as well as convertible senior notes, to raise more than $300 million. The offering of 1,625,000 total shares of common stock at a price of $84.00 per share is slated to bring gross proceeds of approximately $136.5 […]
Nevro Corp.
Stimwave caves in patent spat with Nevro
Stimwave today announced it will cease all sales of its high-frequency spinal cord stimulation systems in exchange for dismissal of a patent infringement lawsuit brought by rival Nevro (NYSE:NVRO). No damages were awarded to Nevro under the settlement. Redwood City, Calif.-based Nevro brought the suit in February 2019, alleging that Stimwave infringed on patents related to […]
Nevro shares rise with Street-beating Q4 results
Nevro (NYSE:NVRO) reported fourth-quarter results today that beat the consensus forecast on Wall Street. The Redwood City, Calif.-based company reported losses of -$13.7 million, or -44¢ per share, on sales of $114.3 million for the three months ended Dec. 31, 2019, for sales growth of 5.9% compared with Q4 2018. Earnings per share were -44¢, 19¢ […]
Nevro names new VP of clinical, regulatory and quality
Nevro (NYSE:NVRO) this week said it appointed Donald Middlebrook as VP of clinical, regulatory and quality. Middlebrook will report directly to CEO and president Keith Grossman. “We’re pleased to have a leader of Don’s caliber join Nevro to advance our clinical pipeline and oversee our global regulatory and quality initiatives,” Grossman said in a news release. […]
The 10 greatest medtech advances of the 2010s
From disposable endoscopes to TAVR to robotic surgery, there’s a whole host of medtech advances widely available now that weren’t around much 10 years ago. “In terms of technological advances, I would put this past decade as one of the most important for medical technology. From connected devices and robotics, to advances in material sciences […]
Nevro launches Senza Omnia spinal cord stimulation system
Nevro (NYSE:NVRO) said today that it won FDA approval for and launched its Senza Omnia spinal cord stimulation system. The Senza Omnia is the first and only SCS system designed to deliver Nevro’s proprietary HF10 therapy, as well as other available SCS frequencies, Nevro said in a news release. Redwood City, Calif.–based Nevro’s Omnia system is […]
Stimwave appeals injunction in Nevro patent war
Stimwave yesterday appealed a preliminary injunction barring it from using higher-frequency neurostim to treat chronic pain in a patent spat with rival Nevro (NYSE:NVRO). Redwood City, Calif.-based Nevro brought the suit in February, alleging that Stimwave infringed on patents related to Nevro’s Senza system and HF10 therapy. The lawsuit, filed in the U.S. District Court for Delaware, […]
Nevro launches clinical trial of diabetic neuropathy treatment
Nevro (NYSE:NVRO) said today that it has completed patient enrollment in a clinical trial of its Senza HF10 therapy for patients with painful diabetic neuropathy. The Redwood City, Calif.-based company said the prospective, multicenter, randomized controlled trial compares its HF10 therapy plus conventional medical management to conventional treatment alone in 216 patients at 18 centers in […]
Nevro beats the Street with Q2 results
Shares in Nevro (NYSE:NVRO) rose this week after the medical device maker topped expectations on Wall Street with its second-quarter financial results. The Redwood City, Calif.-based company posted a net loss of -$28 million on sales of $93.6 million for the three months ended June 30. Compared with the same period last year, Nevro’s revenue fell […]
Nevro wins partial injunction in patent spat with Stimwave
A federal judge in Delaware yesterday granted a preliminary injunction to Nevro Corp. (NYSE:NVRO) barring neuromodulation rival Stimwave from using higher-frequency neurostim to treat chronic pain. Redwood City, Calif.-based Nevro brought the suit in February, alleging that Stimwave infringed on patents related to Nevro’s Senza system and HF10 therapy. The lawsuit, which was filed in the U.S. […]
HeartFlow taps ex-Beaver-Visitec CEO Mead as chief exec | Personnel Moves – May 28, 2019
HeartFlow said today that it named former Beaver-Visitec prez & CEO Dana Mead, Jr., as its new president and CEO, replacing current prez & CEO Dr. John Stevens, who will continue to serve on the board as chair. Prior to joining Beaver-Visitec, Mead served as a strategic advisor and partner in Kleiner Perkins Caufield & […]